MARKET

NBRV

NBRV

Nabriva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5269
-0.0031
-0.58%
After Hours: 0.5400 +0.0131 +2.49% 19:42 09/25 EDT
OPEN
0.5201
PREV CLOSE
0.5300
HIGH
0.5300
LOW
0.5103
VOLUME
1.38M
TURNOVER
--
52 WEEK HIGH
2.230
52 WEEK LOW
0.4850
MARKET CAP
75.78M
P/E (TTM)
-0.5813
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow
The following slide deck was published by Nabriva Therapeutics plc in conjunction with this event.
Seekingalpha · 09/17 20:21
Nabriva Therapeutics Granted New Technology Add-On Payment For XENLETA And CONTEPO By Centers For Medicare & Medicaid Services
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship   -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional
NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship   -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional · 09/10 12:45
Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services
-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship -CONTEPO first Qualified Infectious Disease Product to receive NTAP conditional approval prior to FDA approval DUBLIN, Ireland, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva
GlobeNewswire · 09/10 12:39
Nabriva files for $150M mixed shelf
Nabriva Therapeutics (NBRV) has filed a prospectus for a $150M mixed shelf offering.
Seekingalpha · 09/01 20:59
Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences
DUBLIN, Ireland, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor
GlobeNewswire · 08/31 12:00
Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 12:43
Nabriva Therapeutics plc 2020 Q2 - Results - Earnings Call Presentation
Seeking Alpha - Article · 08/07 14:32
Nabriva Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Updates
GlobeNewswire · 08/06 21:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBRV. Analyze the recent business situations of Nabriva through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBRV stock price target is 1.750 with a high estimate of 2.000 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 82
Institutional Holdings: 37.30M
% Owned: 25.93%
Shares Outstanding: 143.83M
TypeInstitutionsShares
Increased
12
10.63M
New
23
3.97M
Decreased
6
363.21K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman - Supervisory/Independent Director
Daniel Burgess
President/Chief Operating Officer
Steven Gelone
Chief Executive Officer/Director
Theodore Schroeder
Chief Financial Officer/IR Contact Officer
Gary Sender
General Counsel/Secretary
Robert Crotty
Other
Francesco Lavino
Other
Jennifer Schranz
Director
Colin Broom
Independent Director/Supervisory Board
Carrie Bourdow
Independent Director/Supervisory Board
Charles Rowland
Independent Director/Supervisory Board
George Talbot
Independent Director/Supervisory Board
Stephen Webster
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NBRV
Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nabriva Therapeutics PLC - ADR stock information, including NASDAQ:NBRV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBRV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBRV stock methods without spending real money on the virtual paper trading platform.